An on-chip multi-imaging flow cytometry system has been developed to obtain morphometric parameters of cell clusters such as cell number, perimeter, total cross-sectional area, number of nuclei and size of clusters as “imaging biomarkers”, with simultaneous acquisition and analysis of both bright-field (BF) and fluorescent (FL) images at 200 frames per second (fps); by using this system, we examined the effectiveness of using imaging biomarkers for the identification of clustered circulating tumor cells (CTCs). Sample blood of rats in which a prostate cancer cell line (MAT-LyLu) had been pre-implanted was applied to a microchannel on a disposable microchip after staining the nuclei using fluorescent dye for their visualization, and the acquired images were measured and compared with those of healthy rats. In terms of the results, clustered cells having (1) cell area larger than 200 µm2 and (2) nucleus area larger than 90 µm2 were specifically observed in cancer cell-implanted blood, but were not observed in healthy rats. In addition, (3) clusters having more than 3 nuclei were specific for cancer-implanted blood and (4) a ratio between the actual perimeter and the perimeter calculated from the obtained area, which reflects a shape distorted from ideal roundness, of less than 0.90 was specific for all clusters having more than 3 nuclei and was also specific for cancer-implanted blood. The collected clusters larger than 300 µm2 were examined by quantitative gene copy number assay, and were identified as being CTCs. These results indicate the usefulness of the imaging biomarkers for characterizing clusters, and all of the four examined imaging biomarkers—cluster area, nuclei area, nuclei number, and ratio of perimeter—can identify clustered CTCs in blood with the same level of preciseness using multi-imaging cytometry.
Citation: Kim H, Terazono H, Nakamura Y, Sakai K, Hattori A, Odaka M, et al. (2014) Development of On-Chip Multi-Imaging Flow Cytometry for Identification of Imaging Biomarkers of Clustered Circulating Tumor Cells. PLoS ONE 9(8): e104372. https://doi.org/10.1371/journal.pone.0104372
Editor: Thomas Dittmar, Witten/Herdecke University, Germany
Received: January 30, 2014; Accepted: July 10, 2014; Published: August 20, 2014
Copyright: © 2014 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Kanagawa Prefector's local basic science funding for the On-chip Cellomics Project at the Kanagawa Academy of Science and Technology. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Finding irregular cells in blood is fundamental to achieving non-invasive health checks, such as cancer and immune diagnostics. For example, circulating tumor cells (CTCs) are expected to form additional seeds for subsequent growth of tumors –, and quantitative detection of CTCs in the blood – has the potential to achieve minimally invasive cancer diagnosis in comparison with conventional biopsies. One major approach to finding irregular cells is the targeting of specific molecules, molecular biomarkers, on the cell surface , , , , ; however, its application has sometimes had the difficulty of false-negative detection because of the variety of molecular expression properties of targeted cells.
To overcome these difficulties, we developed another system for the recognition of target cells –. In this system, cell samples were applied to a microchannel fabricated on a small microchip, cellular images were taken with a high-speed CCD camera, and target cells were identified depending on their morphological characteristics, such as cellular area and perimeter. These morphological parameters, referred to as “imaging biomarkers” hereafter, are other indexes to identify specific target cells. For example, a large cellular size was indicated for some tumor cells –, and a larger nucleus than in healthy cells is known as one common property of the morphometric phenotype of cancer cells –; therefore, finding target cells using imaging biomarkers, especially using both cell size and nucleus conformation, is useful for the identification of tumor cells. In this study, a real-time cell sorting system to achieve simultaneous processing of imaging biomarkers for both optical image (i.e., total cell configuration) and fluorescent image (i.e., nucleus configuration) was developed, and it was applied to identify irregular cells, especially clustered cells, in a blood sample. According to previous reports on CTC detection, the possibility of the CTCs forming clusters was suggested ; however, clear evidence had not been identified and there have been no quantitative studies on the identification of clustered cells in the blood. Here, a quantitative approach for cluster detection was suggested using imaging biomarkers as detection indexes.
Materials and Methods
Fabrication of microchip
The microchip was fabricated by the following procedure. A mask blank, which was a glass substrate coated with both chromium for light interception and positive photo-resist (AZP1350) for the fabrication of patterns (CBL4006Du-AZP, Clean Surface Technology Co., Kanagawa, Japan), was set to a laser lithography system (DDB-3TH, Neoark, Co., Tokyo, Japan) and a laser (405 nm wavelength) was irradiated onto the mask blank in the same pattern as the microchannel used in this study. After the irradiation, the mask blank was immersed in a developer of the resist (NMD-3, Tokyo Ohka Kogyo Co., Kanagawa, Japan) to remove the resist on which the laser was irradiated; then, a chromium layer was bared at this position. Next, the mask blank was immersed in chromium etching solution (MPM-E350, DNP Fine Chemicals, Co., Kanagawa, Japan), after which the bared chromium layer was removed and a transparent pattern of the microchannel was formed on the substrate. Finally, the whole resist on the mask blank was removed by light irradiation onto the whole of the substrate and immersion of the substrate in the developer; then, a photo mask of the microchannel was fabricated.
On the other hand, a light-curing resin (SU-8 3025, Nippon Kayaku Co., Tokyo, Japan) was spin-coated using a spin coater (1H-DX2, Mikasa, Co., Tokyo, Japan) of 25 µm thickness on a clean Si substrate. The resin-coated substrate was pre-baked at 95°C for 15 min, set in a mask aligner with the fabricated photo mask (MA-20, Mikasa), and the light (365 nm wavelength) was irradiated through the mask to harden the resin with the pattern of the microchannel. The substrate was heated at 65°C for 1 min and 95°C for 5 min sequentially to promote hardening of the resin, and excess resin was removed by immersing the substrate in SU-8 developer (Nippon Kayaku). A mold of the microchannel was then fabricated using the resin on the Si substrate.
To fabricate the chip, poly(dimethylsiloxane) (PDMS; SYLGARD 184 silicon elastomer, Dow Corning Co., Midland, MI, USA) was dropped onto the fabricated mold in sol state, and heated at 90°C for 1 h to harden the PDMS. The PDMS on which the pattern of the microchannel was transferred was peeled off from the mold and stuck with cleaned cover glass. Finally, plastic columns for the application of solvents including sample blood were pasted on the PDMS with epoxy resin; then, the microchip to be used in this study was fabricated.
Preparation of sample blood
This study was carried out in strict accordance with the Act on Welfare and Management of Animals of the Ministry of the Environment, Japan. The protocol was approved by the animal experiment committee of the Kanagawa Cancer Center (permit number 21-02). MAT-LyLu is a rat prostate cancer cell line established from the original Dunning R3327 tumor maintained by in vivo passage of a prostate cancer that spontaneously occurred in a Copenhagen rat . This cell line was a generous gift from the original founders through Hisao Ekimoto, Ph.D., at the Oncology Section, Laboratory of Biology, Nippon Kayaku Co., Ltd., and was maintained in our laboratory.
To obtain blood containing cancer cells, the MAT-LyLu was adjusted to 5×106 cells in 200 µL of cell culture medium (RPMI 1640, Life Technologies Co., Grand Island, NY, USA), and implanted into the dorsal subcutaneous tissue of a Copenhagen rat (male, 6 weeks old). At 2 weeks after implantation, blood of the rat was collected from the subclavian vein using a collection tube containing heparin. The blood was hemolyzed using commercial reagent (BD Pharm Lyse, without fixative, BD Biosciences, San Jose, CA, USA) for 10 min, washed along with 200× g centrifugation for 5 min and re-suspended two times in phosphate-buffered saline (PBS) containing 1% bovine serum albumin, suspended in PBS containing 100 ng/mL Hoechst 33258, and then incubated for 10 min to stain cellular nuclei. The sample was washed again along with centrifugation 3 times, suspended in 5% glucose solution, and applied to the sample inlet on the chip.
The prepared sample blood was applied to the sample inlet on a fabricated microchip with a sample volume of 50 µL in an assay. The same buffer with the sample cell suspension (i.e., 5% glucose) was also used as a sheath buffer, and was applied to the sheath buffer inlet. Air pressure was applied onto both sample and sheath buffer inlets simultaneously using a syringe pump to introduce these liquids into the microchannels. Before starting the experiments, flow velocity was calibrated by taking images of calibration beads using a CCD camera (Ditect Co., Tokyo, Japan) as the shift of bead position in the microchannel within a few frames of the images, and typically, 1 kPa pressure achieved flow velocity of about 3 mm/sec at the position after the meeting of sample and sheath flows. Multi-imaging observations of sample blood were then performed through the multi-view unit with 3 mm/sec flow velocity and 200 fps acquisition rate.
Comparative genomic hybridization analysis
Rat genome comparative genomic hybridization (CGH) microarray 244A (Agilent Technologies, Santa Clara, CA, USA) was used to perform array CGH on genomic DNA obtained from the MAT-LyLu cell line according to the manufacturer's instructions. A DNA sample obtained from liver tissue of a healthy Copenhagen rat was used as a reference. Genomic DNAs were extracted using a QIAamp DNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The DNA concentration was determined with PicoGreen dsDNA Quantitation Reagent (Life Technologies). Agilent Genomic Workbench (Agilent Technologies) was used to analyze chromosomal patterns using an ADM-2 algorithm setting a threshold of 5.0.
Copy number assay
The gene copy numbers for csrp2 and zdhhc17 were determined using TaqMan Copy Number Assays according to the manufacturer's instructions (Applied Biosystems, Foster City, CA, USA). The gene-specific primers and TaqMan probes were used in the experiments had the following sequences. Rat csrp2 primers were: sense, 5′-GGACTAAATGGATTGATGCCACTCT-3′; antisense, 5′-GTCCCTGCTTCAAAGAACTGTCT-3′; probe, 5′-FAM-AAGAGCAAGAAAGGAAACCC-MGB-NFQ-3′. Rat zdhhc17 primers were: sense, 5′-GCCCTACTGCATGCATGATACA-3′; antisense, 5′-GGGCTGTTTTGCACATGAAATTCAA-3′; probe, 5′-FAM-CTGGACAGCATCTGCTAGTATAC-MGB-NFQ-3′. Rat rpp40 primers were: sense, 5′-GTATGACACTGGCATGGAAGTCT-3′; antisense, 5′-CTTGCAGGTCCTCTGTGGAT-3′; probe, 5′-FAM-CCTGGCAATCAAAGTTAGGCTTAG-MGB-NFQ-3′. Genomic DNAs obtained from collected samples using the cell sorting system were extracted using a QIAamp DNA Micro kit (Qiagen) according to the manufacturer's instructions. The DNA concentrations were determined with PicoGreen dsDNA Quantitation Reagent. Rat rpp40 was used as an internal control. Genomic DNAs obtained from MAT-LyLu cell line and healthy rat liver were used as positive and negative controls, respectively.
Development of on-chip multi-imaging flow cytometry system
The on-chip multi-imaging flow cytometry system (Fig. 1) was composed of seven major modules as an improvement of previous systems –, : (i) microchip, (ii) bright-field (BF) light source, (iii) fluorescent (FL) excitation and detection, (iv) multi-view, (v) CCD camera, (vi) sorting, and (vii) controller, as numbered in Fig. 1 (a). In the BF light source module, an LED (625 nm wavelength) was used as a source for taking BF images and was irradiated from the top of the chip. This allowed simultaneous measurements of both BF and FL images, avoiding interference of the wavelengths during the measurements. An objective lens having 20× magnification and a 0.75 numerical aperture was set to the system, which allowed clear cell images to be taken within the depth range of the microchannel (25 µm) . The FL excitation and detection modules contained three excitation lasers (375, 488, and 515 nm) and photomultipliers (PMTs), respectively, to monitor three different FL signals, which allowed conventional FL detection with labeling of target biomarkers. The controller module consisted of two independent units: one calculated FL signals and the other processed imaging biomarkers in multi-view images. Maximum frequencies of calculations were 10,000 frequencies per second (fps) for controller 1, which calculated FL intensities, and 200 fps for controller 2, which processed imaging biomarkers for the current system. According to the adjustment of suitable thresholds for these parameters, feedback signals could be sent to the sorting module. The sorting module was composed of a direct current (DC) source and electrodes connected with a microchip, and could apply DC voltages to cells flowing in a microchannel of the chip to purify target cells under feedback signals, if necessary. Figure 1 (b) shows the principle of the multi-view module ,  used in this study. Firstly, optical paths between BF (red) and FL (blue) lights were separated using dichroic mirror A, as indicated in the figure. Next, angles of mirrors A and B were adjusted; then, BF and FL images were projected onto each half of a CCD component in the camera. An overview of the total system is shown in Fig. 1 (c). The system has a desktop size of 60 cm×60 cm.
(a) Summary of the on-chip multi-imaging flow cytometry system. The system was composed of seven major modules: (i) microchip, (ii) bright-field (BF) imaging, (iii) fluorescent (FL) detection, (iv) multi-view, (v) CCD camera, (vi) sorting, and (vii) controller, as numbered in the figure. (b) Summary of the multi-view module. (c) A photograph of the system.
Figure 2 shows the microchip designed to be suitable for this study. The chip body was fabricated with poly(dimethylsiloxane) (PDMS) attached to a cover glass to apply optical transparency in the observation. Microchannels were placed between the PDMS and the bottom cover glass in the chip with a 2 mmφ buffer entrance penetrating the PDMS. The upper stream of the microchannel was branched into three channels: the center connected with the sample inlet and the others were a sheath buffer inlet. Both sample and sheath buffers were introduced into the channel with application of air pressure onto both sample and sheath buffer inlets, simultaneously (Fig. 2 (c)). After the meeting of sample and sheath flows, the width of the sample flow was focused in the central one-third, which allowed imaging of each single cell upon the arrangement of all the cells in a straight line.
(a) Diagonal, (b) top, and (c) side views of the microchip used in this study. (d) A photograph of the chip. Total chip size is 50 mm×40 mm.
Images of the linearly arranged cells were obtained through the multi-view module and processed by the system (see Fig. 1), and when a target cell was found, DC voltage (typically 40 V with 100 µsec length) was applied to the cell through the agarose gel electrode (Fig. 2 (a) and (b)) to change its course in the collection channel , . Figure 3 shows a typical example of the cell sorting with a blood sample of a cancer-implanted rat. As shown in this figure, target cells were set into cell clusters having a large BF area, and once the value of the BF area of the observed cell exceeded the pre-adjusted threshold value, 300 µm2 in this model case, a sorting voltage was applied to the cell and, finally, target cells were collected into the target collection reservoir. Figures 3 (a) and (b) show pictures taken for discarding (a) and collection (b) reservoirs, respectively. As shown in Fig. 3 (b), large cell clusters (indicated by arrows in the figures) were collected into the collection reservoir. On the other hand, single cells or small cell clusters were collected into the discarding reservoir (Fig. 3 (a)), indicating the success of target collection using one imaging biomarker, BF area, as a collection parameter. The sorting capacity, which has been determined as the ratio between the number of target cells automatically detected by the system and the actual number of cells in the collection reservoir, was 24%. The low capacity of target cell collection was caused by the higher threshold setting in both recognition and collection processes to prevent ‘false positive’ sample collection. When the commercially available microbeads were used as a model target in this system, sorting capacity increased to 91%.
Two photographs of the discarded reservoir (a) and the collection reservoir (b) indicated in the chip photograph are shown. Clustered cells are indicated by white arrows. Bars, 100 µm.
As shown in Fig. 3, target cells can be recognized by comparison of the imaging biomarkers with the threshold values pre-adjusted in the system. Figure 4 shows the detail of image processing in the system to obtain imaging biomarkers. Firstly, a background image, which was taken before the assay of flow cytometry, was subtracted from the obtained image with reductions of 8-bit grayscale values in each pixel. Next, the subtracted image was transformed to a binary image using a suitable threshold and pixel errors in the cell, which appeared by almost the same contrast in the cell as in the background, were filled (Fig. 4, asterisk); then, an extracted cell image was obtained. Finally, imaging biomarkers were calculated from the extracted cell image. In the current system, cell area (S) and actual perimeter (Pa) were obtained from the BF image, and nucleus area (Sn) and number of nuclei (Nn) were obtained from the FL image. Additionally, the perimeter ratio, R, which was obtained as the ratio between Pa and the perimeter calculated from S (Pc) , was also obtained. These calculations were performed in real time at 200 fps using controller 2 in Fig. 1, and in this study, manual calculations of the imaging biomarkers, including a few modifications for apparently failed auto-calculations caused by the failure of continuous detection of the cell perimeter in the hole filling procedure, were also performed as post-processing to confirm the reliabilities of the obtained imaging biomarker values.
Firstly, photographs of both a cell and the background were taken. Next, the background image was subtracted from the cell image and holes were filled. Finally, imaging biomarkers, S, Sn, Nn, and R, were calculated. Bars, 10 µm. The hole-filling procedure is explained as indicated by an asterisk. Bar, 10 µm.
Detection of clustered cells in cancer-implanted rat blood using imaging biomarkers
After the success of the system development, its performance for the identification of specific target cells using imaging biomarkers was quantitatively evaluated. Blood of a rat in which a rat prostate cancer cell line (MAT-LyLu) had been implanted was chosen as a model sample, and clustered cells in the blood were set as a target for the detection using imaging biomarkers with the developed system. One approach anticipated to achieve successful detection of the clusters is the use of cell area; therefore, areas in BF images (i.e., total cell area, S) and FL images (i.e., total nucleus area, Sn) were measured using the system. Figures 5 and 6 are histograms of S (Fig. 5) and Sn (Fig. 6) for cells in the cancer-implanted blood (N = 4375), shown with healthy rat blood as its control (N = 1599). Detailed numbers including S and Sn are also summarized in Table 1. From the results, clustered cells were observed at a count of 237 in cancer-implanted samples (5.4% of the total) and a count of 56 in the control (3.5% of the total). In addition, two clear threshold values were found in both S and Sn; that is, (a) all cells having S larger than 140 µm2 (count of 61, 1.4% of the total, for cancer-implanted samples and 13, 0.8% of the total, for the control) and Sn larger than 80 µm2 (count of 34, 0.8% of the total, for cancer-implanted samples and 1, 0.1% of the total, for the control) were clustered cells, as indicated by the dotted lines in Figs. 5 and 6, and (b) the clustered cells having S larger than 200 µm2 (count of 27, 0.6% of the total) and Sn larger than 90 µm2 (count of 26, 0.6% of the total) were specifically observed in cancer cell-implanted blood. These results indicate that some cell clusters can be identified by using S and Sn (61 of 237, 26% of all clusters, for S and 34 of 237, 14% of all clusters, for Sn) as parameters for detection.
Two threshold values (a) and (b) for cluster identifications are indicated as dotted and dashed lines.
Two threshold values (a) and (b) for cluster identifications are indicated as dotted and dashed lines.
Obtained pictures were manually analyzed one by one with measured values of S and Sn. Figure 7 shows examples of single- and double-cell images having one, two, or three nuclei obtained from cancer-implanted and control blood, respectively. As shown in Fig. 7, the following 3 results were obtained: (i) single cells having multiple nuclei numbering more than two were specifically included in the cancer cell-implanted blood (count of 133, 3.2% of total single cells in cancer-implanted samples), (ii) two-cell clusters having only one nucleus seemed to be single cells to which a small particle (possibly debris of a hemolyzed red cell) was attached (count of 126, 72% of total two-cell clusters in cancer-implanted samples and count of 41, 84% of total two-cell clusters in control), and (iii) two-cell clusters having two nuclei were either true clusters or two independent cells flowing alongside each other (count of 48, including 2 clusters having 3 nuclei caused by the inclusion of a cell with multiple nuclei, 28% of total two-cell clusters in cancer-implanted samples and count of 8, 16% of total two-cell clusters in control). The first of these results shows the potential for the detection of implanted cancer cells having multiple nuclei, and the second can be thought of as single cells in general. The third in principle makes it difficult to distinguish two-cell clusters from two single cells using pictures; therefore, such two-cell “clusters” were also contained in control blood.
Each data count (n) indicates the image number having the same cluster size and Nn. Bars, 20 µm.
Figure 8 shows typical clustered cells composed of more than 3 cells. As shown in the figure and also in Table 1, a few clusters composed of more than 3 cells were also detected in control blood (count of 7 in total), with the maximum cell number of 6. However, they seemed to be single or two independent cells to which small particles were attached (i.e., the same as result (ii) in Fig. 7), which could also be confirmed by the number of nuclei, Nn, in the cluster, which had a maximum of 2. On the other hand, clusters contained in cancer-implanted blood were composed of more than 3 cells, with 15 cells at maximum, which was also confirmed by Nn in the cluster being more than 3. It is unlikely for more than 3 cells to be flowing alongside each other; therefore, we concluded that clusters composed of more than 3 cells containing more than 3 nuclei were truly clustered cells in the blood. Such large clusters were contained in cancer cell-implanted blood at a count of 33 (7 counts, 21% of 3-cell clusters, 12 counts, 75% of 4-cell clusters, 14 counts, 100% of ≥5-cell clusters, and 0.8% of the total). Measured values of Nn are summarized in Fig. 9 (a) (and also in Table 1). As shown in this figure, more than 99% of images in control blood had a single nucleus, and cell clusters having more than 3 nuclei were not contained in the blood. Figure 9 (b) also shows Nn summarized from the perspective of cluster size. As shown in the figure, large clusters in cancer-implanted blood had many nuclei, typically more than 3, indicating the possibility of the cluster formation of CTCs in the blood.
Each data count (n) indicates the image number having the same cluster size and Nn. Bars, 20 µm.
(a) A histogram of Nn obtained from cancer cell-implanted and control blood. (b) The relationship between Nn and cell cluster size.
As shown in the above results, Nn is one useful imaging biomarker to identify cell clusters in blood; however, only using this marker for identification is insufficient because single cells having multiple nuclei were also contained in cancer cell-implanted blood, as shown in Fig. 7; therefore, we evaluated another imaging biomarker, perimeter ratio (R), for the identification of clustered cells. R is defined as the ratio between the actual perimeter obtained from the cell image and the perimeter calculated with a circle approximation of S. A low value of R indicates distorted conformation of the cell away from a circular shape, which was expected for cell clusters. Figure 10 shows the relationship between the average value of R and cell cluster size for a cancer-implanted sample (detailed numbers are also shown in Table 1). As shown in the figure and table, all single cells had R higher than 0.90, with an average of 0.96, indicating that all cells having R smaller than 0.90 were clusters composed of more than 2 cells. On the other hand, R values for clusters composed of more than 2 cells were lower than 0.90 on average, and in detail, 131 clusters in cancer-implanted samples (55% of all clusters) and 55 clusters in control (98% of all clusters) had R lower than 0.90. Moreover, all large clusters composed of more than 3 cells having more than 3 nuclei, specifically observed only in cancer-implanted blood, had R lower than 0.90. These results indicate that more than half of the clusters, especially large clusters, could be identified by using R as an imaging biomarker.
According to the above results, large cluster formation of cancer cells in the blood was strongly expected. To confirm this, clusters larger than 300 µm2 were collected by performing cell sorting in the chip, and their cell types were identified by measuring genome errors in the cells. Firstly, target genes that were included in the MAT-LyLu chromosome with abnormal copy numbers were searched by comparative genomic hybridization (CGH) assay using the cell line, with liver tissue of the rat as a reference. Two particularly abundant genes, csrp2 and zdhhc17 located on chromosome 7q13, were found (Fig. 11 (a)) and set as target genes for the identification of cancer cells in the blood. Next, the TaqMan copy number assay was performed for cells collected in both the collection reservoir and the discarded reservoir (see Fig. 3). From the results, increases of copy numbers for both csrp2 and zdhhc17 were specifically observed for clustered cells collected in the collection reservoir (Fig. 11 (b)). These results indicate that large clusters, which were specifically observed in cancer cell-implanted blood, were CTCs.
(a) Results of CGH assays performed for the MAT-LyLu cell line. Liver tissue of the rat was used as a reference. Gene amplifications for csrp2 and zdhhc17 located on chromosome 7q13 were found. (b) Results of TaqMan copy number assays performed with clusters larger than 300 µm2 collected in the collection reservoir, and cells smaller than 300 µm2 collected in the discarded reservoir. Results of the assays for the MAT-LyLu cell line (positive control) and liver tissue (negative control) are also shown.
In this study, four imaging biomarkers, cell area, nucleus area, number of nuclei, and perimeter ratio (S, Sn, Nn, and R),were evaluated for the identification of cell clusters in the blood. From the results, some threshold values were obtained for each imaging biomarker, namely, (1) S larger than 200 µm2 and (2) Sn larger than 90 µm2 were specific to cancer cell-implanted blood. In addition, (3) Nn higher than 3 was also specific to cancer cell-implanted blood. Finally, (4) all clustered cells composed of more than 3 cells having Nn higher than 3, which was specific to cancer cell-implanted blood, had R lower than 0.90. According to these results, the use of R is one useful approach for the identification of clustered cells having multiple nuclei numbering more than 3, which are specific to cancer cell-implanted blood. S and Sn are also useful parameters for the identification of extremely large clusters, which are quite likely to be CTCs. For small clusters composed of two cells, it is in principle difficult to distinguish whether the cluster is an actual cluster or two independent cells flowing alongside each other by using image-based analysis. One potential approach to distinguish these possibilities is the combination of the image-based analysis suggested in this study with a molecular analytical approach, such as quantitative gene copy number assays of the targeted cells. The system developed in this study has been combined with a cell sorting unit and can perform the combination measurement of multi-imaging analysis with molecular analysis, as shown in Fig. 11, which indicates the advantage of our developed system.
For the detection of CTCs, some methods were suggested. The principles were in general separated into two kinds; one was based on the chemical reaction and the other was physical detection. The former is in general based on the labeling of target molecules on the CTCs with antibodies, and it was sometimes combined with microfabrication technologies to improve detection sensitivities , . However, this approach sometimes yielded false-negative detection because of the variety of molecular expression levels in CTCs. For this latter case, various physical parameters of CTCs such as cell diameter , ,  and dielectrophoretic properties  have been used with a combination of microfabrication technologies. According to the results in this study, cell size (S) is one useful parameter to find irregular cells in blood samples such as clustered cells; however, the use of only one parameter is insufficient for the exhaustive detection of CTCs. Our developed system can use various parameters including both chemical and physical properties to find target cells, which would also be useful for the detection of various CTCs.
In this study, large clusters were specifically observed in cancer cell-implanted blood, and an approach for finding these clusters in the blood has possibility for the development of a new cancer metastasis diagnostic method. Results in this study were obtained using hemolyzed blood samples in vitro; therefore, the large cluster formations should also be confirmed for blood in vivo as a next step to achieve such a new diagnostic method. One possibility for the mechanism of large cluster formation is an aggregation of implanted cancer cells by immune reaction of the rat with antibody formation. In this study, blood samples were picked up from the rat 2 weeks after implantation; therefore, time-course measurements of cluster formations after implantation might be one useful way to confirm the above possibility, and our developed system can also be used to confirm this.
In this study, an on-chip multi-imaging flow cytometry system was developed to find cell clusters in blood samples. The system can take both BF and FL pictures simultaneously, and can obtain imaging biomarkers; cell area, nucleus area, number of nuclei, and perimeter ratio (S, Sn, Nn, and R), in real time. By using the developed system, sample blood of rats in which cancer cells had been pre-implanted was measured and compared with that of healthy rats. In terms of the results, clustered cells having (1) S larger than 200 µm2 and (2) Sn larger than 90 µm2 were specifically observed in cancer cell-implanted blood, but were not observed in healthy rats. In addition, (3) Nn higher than 3 was specific for cancer-implanted blood and (4) R smaller than 0.90 was specific for all clusters having Nn higher than 3, which were specific for cancer-implanted blood. Finally, quantitative gene copy number assay was performed for the large clusters, and they were shown to be CTCs. These results indicate the usefulness of the imaging biomarkers for characterizing clusters, and that the developed system is useful to identify clustered CTCs in blood.
Conceived and designed the experiments: HK TA KN YM KY. Performed the experiments: HK HT YN KS AH MO MG TA. Analyzed the data: HK KS AH MO MG TA KN YM KY. Contributed reagents/materials/analysis tools: HK HT YN KS AH MO MG TA KN YM KY. Wrote the paper: HK KY.
- 1. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781–791.
- 2. Sethi N, Kang Y (2011) Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 11: 735–748.
- 3. Yu M, Stott S, Toner M, Maheswaran S, Haber DA (2011) Circulating tumor cells: approaches to isolation and characterization. J Cell Biol 192: 373–382.
- 4. Davis JA, Inglis DW, Morton KJ, Lawrence DA, Huang LR, et al. (2006) Deterministic hydrodynamics: taking blood apart. Proc Natl Acad Sci U S A 103: 14779–14784.
- 5. Gascoyne PR, Noshari J, Anderson TJ, Becker FF (2009) Isolation of rare cells from cell mixtures by dielectrophoresis. Electrophoresis 30: 1388–1398.
- 6. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, et al. (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 450: 1235–1239.
- 7. Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, et al. (2010) Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A 107: 18392–18397.
- 8. Zheng S, Lin HK, Lu B, Williams A, Datar R, et al. (2011) 3D microfilter device for viable circulating tumor cell (CTC) enrichment from blood. Biomed Microdevices 13: 203–213.
- 9. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, et al. (2006) Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res 12: 6403–6409.
- 10. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, et al. (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13: 7053–7058.
- 11. Takahashi K, Hattori A, Suzuki I, Ichiki T, Yasuda K (2004) Non-destructive on-chip cell sorting system with real-time microscopic image processing. J Nanobiotechnology 2: 5.
- 12. Hayashi M, Hattori A, Kim H, Terazono H, Kaneko T, et al. (2011) Fully automated on-chip imaging flow cytometry system with disposable contamination-free plastic re-cultivation chip. Int J Mol Sci 12: 3618–3634.
- 13. Yasuda K, Hattori A, Kim H, Terazono H, Hayashi M, et al. (2013) Non-destructive on-chip imaging flow cell-sorting system for on-chip cellomics. Microfluidics and Nanofluidics 14: 907–931.
- 14. Vona G, Sabile A, Louha M, Sitruk V, Romana S, et al. (2000) Isolation by size of epithelial tumor cells - A new method for the immunomorphological and molecular characterization of circulating tumor cells. American Journal of Pathology 156: 57–63.
- 15. Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Janne PA, et al. (2011) A New Device for Rapid Isolation by Size and Characterization of Rare Circulating Tumor Cells. Anticancer Research 31: 427–441.
- 16. Hosokawa M, Kenmotsu H, Koh Y, Yoshino T, Yoshikawa T, et al. (2013) Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. Plos One 8.
- 17. Hosokawa M, Yoshikawa T, Negishi R, Yoshino T, Koh Y, et al. (2013) Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer. Analytical Chemistry 85: 5692–5698.
- 18. Abdalla F, Boder J, Markus R, Hashmi H, Buhmeida A, et al. (2009) Correlation of nuclear morphometry of breast cancer in histological sections with clinicopathological features and prognosis. Anticancer Res 29: 1771–1776.
- 19. Buhmeida A, Algars A, Ristamaki R, Collan Y, Syrjanen K, et al. (2006) Nuclear size as prognostic determinant in stage II and stage III colorectal adenocarcinoma. Anticancer Res 26: 455–462.
- 20. de Andrea CE, Petrilli AS, Jesus-Garcia R, Bleggi-Torres LF, Alves MT (2011) Large and round tumor nuclei in osteosarcoma: good clinical outcome. Int J Clin Exp Pathol 4: 169–174.
- 21. Deans GT, Hamilton PW, Watt PC, Heatley M, Williamson K, et al. (1993) Morphometric analysis of colorectal cancer. Dis Colon Rectum 36: 450–456.
- 22. Dundas SA, Laing RW, O'Cathain A, Seddon I, Slater DN, et al. (1988) Feasibility of new prognostic classification for rectal cancer. J Clin Pathol 41: 1273–1276.
- 23. Meachem MD, Burgess HJ, Davies JL, Kidney BA (2012) Utility of nuclear morphometry in the cytologic evaluation of canine cutaneous soft tissue sarcomas. J Vet Diagn Invest 24: 525–530.
- 24. Sokmen S, Sarioglu S, Fuzun M, Terzi C, Kupelioglu A, et al. (2001) Prognostic significance of angiogenesis in rectal cancer: a morphometric investigation. Anticancer Res 21: 4341–4348.
- 25. Tennant TR, Kim H, Sokoloff M, Rinker-Schaeffer CW (2000) The Dunning model. Prostate 43: 295–302.
- 26. Hattori A, Yasuda K (2010) Comprehensive Study of Microgel Electrode for On-Chip Electrophoretic Cell Sorting. Japanese Journal of Applied Physics 49: 06GM04.
- 27. Hattori A, Kim H, Terazono H, Odaka M, M G, et al. (2014) Identification of cells using morphological information of bright field/fluorescent multi-imaging flow cytometer images. Japanese Journal of Applied Physics in press.
- 28. Kinosita K Jr, Itoh H, Ishiwata S, Hirano K, Nishizaka T, et al. (1991) Dual-view microscopy with a single camera: real-time imaging of molecular orientations and calcium. J Cell Biol 115: 67–73.
- 29. Nomura F, Kaneko T, Hattori A, Yasuda K (2011) Label-Free Shape-Based Selection of Cardiomyocytes with on-Chip Imaging Cell Sorting System. J Bioproces Biotechniq S3: 003.